Stay updated on Oral Insulin Immune Effects in Type 1 Diabetes Risk Clinical Trial

Sign up to get notified when there's something new on the Oral Insulin Immune Effects in Type 1 Diabetes Risk Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral Insulin Immune Effects in Type 1 Diabetes Risk Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site now displays a new global revision notice (v3.4.2) and older maintenance notices (including a funding lapse notice and v3.4.1) were removed. These updates are administrative and do not affect the study details or data presented on this page.
    Difference
    0.4%
    Check dated 2026-02-11T02:19:33.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and updated the page revision to v3.4.1 (replacing v3.4.0).
    Difference
    0.4%
    Check dated 2026-02-04T00:22:23.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Glossary display was added and QC-related metadata (Last Update Submitted that Met QC Criteria) and a new page revision (v3.4.0) were updated; core study details remain unchanged.
    Difference
    0.3%
    Check dated 2026-01-27T23:51:22.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Added related topics: Type 1 diabetes and MedlinePlus Genetics to the page.
    Difference
    0.1%
    Check dated 2026-01-20T23:52:36.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.3 to v3.3.4. This is a minor metadata update and does not affect study details or page content.
    Difference
    0.0%
    Check dated 2026-01-14T01:44:22.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The Locations section now includes additional site locations across California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Washington, Victoria (Australia), and Ontario (Canada). The HHS Vulnerability Disclosure link was removed.
    Difference
    2%
    Check dated 2025-12-23T14:27:31.000Z thumbnail image

Stay in the know with updates to Oral Insulin Immune Effects in Type 1 Diabetes Risk Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral Insulin Immune Effects in Type 1 Diabetes Risk Clinical Trial page.